Zhejiang Hisoar Pharmaceutical (002099) Fundamentals 2026 — P/E 366.2x, Revenue Analysis | SniperIQ
Zhejiang Hisoar Pharmaceutical (002099) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥8.1B, trading at ¥4.98 on the SHZ. This SniperIQ fundamentals page covers Zhejiang Hisoar Pharmaceutical's valuation (P/E 366.2x, P/B 1.6x), profitability (net margin -4.0%), revenue (¥1.9B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Zhejiang Hisoar Pharmaceutical's market cap?
Zhejiang Hisoar Pharmaceutical (002099) has a market capitalization of approximately ¥8.1B, trading at ¥4.98 on the SHZ. Market cap moves with the live share price.
What is Zhejiang Hisoar Pharmaceutical's P/E ratio?
Zhejiang Hisoar Pharmaceutical's trailing twelve-month P/E ratio is 366.2x, with a price-to-book (P/B) of 1.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Zhejiang Hisoar Pharmaceutical?
Zhejiang Hisoar Pharmaceutical runs a net profit margin of -4.0%, a gross margin of 23.6%, and an operating margin of -4.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Zhejiang Hisoar Pharmaceutical generate?
Zhejiang Hisoar Pharmaceutical reported revenue of ¥1.9B for fiscal year 2025, with net income of -¥91M and earnings per share (EPS) of -0.06. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Zhejiang Hisoar Pharmaceutical pay a dividend?
Zhejiang Hisoar Pharmaceutical does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Zhejiang Hisoar Pharmaceutical financially healthy?
Zhejiang Hisoar Pharmaceutical carries a debt-to-equity ratio of 0.28x and a current ratio of 1.20x, with a market beta of 0.36. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Zhejiang Hisoar Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Zhejiang Hisoar Pharmaceutical (002099) the key facts are: market cap ¥8.1B, P/E 366.2x, revenue ¥1.9B, 52-week range 4.87-9.09. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Zhejiang Hisoar Pharmaceutical's full fundamentals live
Get Zhejiang Hisoar Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.